John Philip Bamforth - 13 Jun 2024 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
Director
Signature
/s/ John Philip Bamforth by Dale A. Sander as Attorney-in-Fact
Issuer symbol
HUMA
Transactions as of
13 Jun 2024
Net transactions value
$0
Form type
4
Filing time
17 Jun 2024, 16:11:02 UTC
Previous filing
17 Jun 2024
Next filing
16 Jun 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Award $0 +75,000 $0.000000 75,000 13 Jun 2024 Common Stock 75,000 $7.20 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028.